A Randomized,Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson#s Disease

HUMAN CLINICAL TRIAL - CONFIDENTIAL To assess the safety and tolerability of the daily oral administration of nilotinib (150-300mg once daily) in moderate/advanced and early/de novo PD participants.